



Omthera Contact:

Christian Schade
Chief Financial Officer
Omthera Pharmaceuticals
908-741-6402
CSchade@Omthera.com

Omthera Media Relations:

Eric Goldman
Vice President Public Relations
Rx Communications Group, LLC
917-322-2563
egoldman@rxir.com

**Omthera Pharmaceuticals, Inc. to Present at the 30th Annual
J.P. Morgan Healthcare Conference**

Princeton, NJ, January 4, 2012 -- Omthera Pharmaceuticals, Inc., a privately-held emerging specialty pharmaceuticals company, announced today that Jerry Wisler, President and Chief Executive Officer, will present at the 30th Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2012 at 8:30am PST at The Westin St. Francis Hotel, San Francisco, CA.

About Omthera Pharmaceuticals, Inc.

Founded in 2008, Omthera Pharmaceuticals, Inc. is a privately held, emerging specialty pharmaceuticals company focusing its efforts on the clinical development of new therapies for dyslipidemia. Led by a team of experts with exceptional experience in developing new therapies for lipid disorders, Omthera is dedicated to developing innovative therapies for the millions of patients who have elevated triglyceride levels and increased risk of cardiovascular disease. In March 2011, the Company initiated a pivotal Phase III clinical trial for its lead product candidate, Epanova™, an Omega-3 fatty acid compound in development as a triglyceride-lowering adjunct therapy to diet in patients with very high triglycerides (≥ 500 mg/dL). In August, 2011, Omthera initiated a Phase III trial for Epanova in patients with high triglycerides (≥ 200 mg/dL and ≤ 500 mg/dL) currently on statin therapy. For more information, please visit www.omthera.com.

###